OncoMethylome Sciences Announces Warrant Exercise

Liege (Belgium) - May 29, 2009, 18:00 CET - OncoMethylome Sciences (Euronext Brussels: ONCOB, Euronext Amsterdam: ONCOA), today announced that an additional 24,540 common shares have been issued by the company in exchange for EUR 110 thousand as the result of the exercise of warrants by some employees and consultants of the company. The majority of the exercised warrants were granted in May 2004 and were scheduled to expire in May 2009 if not exercised. As a result of this transaction, OncoMethylome now has 13,185,614 shares outstanding. To download this press release as a PDF, click here: Press release About OncoMethylome Sciences OncoMethylome Sciences (Euronext Brussels: ONCOB; Euronext Amsterdam: ONCOA) is a molecular diagnostics company developing gene methylation tests to assist physicians in effectively detecting and treating cancer. Specifically, the company's tests are designed to help the physician (i) accurately detect cancer in early stages of cancer development, (ii) predict a patient's response to drug therapy, and (iii) predict the likelihood of cancer recurrence. OncoMethylome boasts a broad product development pipeline consisting of over ten products and a solid partnering record. The company collaborates with leading international molecular oncology research centers, such as The Johns Hopkins University, and has a number of commercial and collaborative partnerships with Veridex LLC, a Johson & Johnson company, LabCorp, Schering-Plough Corp., GlaxoSmithKline Biologicals, Abbott, Millipore Corporation's BioScience Division, EXACT Sciences Corp., Merck KGaA and Qiagen. OncoMethylome's products are based on methylation technology invented by Johns Hopkins University (USA). Established in January 2003, OncoMethylome has offices in Liege and Leuven (Belgium), in Durham, NC (USA), and in Amsterdam (the Netherlands). For more information please contact: Philip Devine Tel. +32-479-505-885 ir@oncomethylome.com www.oncomethylome.com This press release contains forward-looking statements and estimates with respect to the anticipated future performance of OncoMethylome and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the Company's control, and may turn out to be materially different. This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.